Intellia Therapeutics, Inc. (NTLA)
Market Cap | 968.58M |
Revenue (ttm) | 43.09M |
Net Income (ttm) | -522.28M |
Shares Out | 101.85M |
EPS (ttm) | -5.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,537,372 |
Open | 9.01 |
Previous Close | 9.21 |
Day's Range | 8.96 - 9.58 |
52-Week Range | 8.96 - 34.87 |
Beta | 1.80 |
Analysts | Buy |
Price Target | 50.53 (+431.34%) |
Earnings Date | Feb 20, 2025 |
About NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers ... [Read more]
Financial Performance
In 2023, Intellia Therapeutics's revenue was $36.28 million, a decrease of -30.40% compared to the previous year's $52.12 million. Losses were -$481.19 million, 1.48% more than in 2022.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $50.53, which is an increase of 431.34% from the latest price.
News

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the...

Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the...

Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intelli...

Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intelli...

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intelli...

Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the...

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027, despi...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the...

Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intelli...

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intelli...

Intellia Therapeutics: Buying The Path To Commercialization
Intellia Therapeutics, Inc. is undergoing strategic reorganization, halting NTLA-3001, and reducing workforce by 27% to extend cash runway into 2027, focusing on late-stage programs NTLA-2002 and Nexi...

Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intelli...

Why Is Intellia Therapeutics Stock Trading Lower On Friday?
On Thursday, Intellia Therapeutics Inc NTLA outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z.

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therap...

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Intellia initiated the Phase 3 HAELO trial for NTLA-2002, targeting lifelong control of hereditary angioedema (HAE) with a single-dose CRISPR-based therapy. Positive Phase 2 NTLA-2002 data showed most...

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the stage for a modest rally. While last month'...

Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Lina Li - Senior Director of Investor Relations and Corporate Communication...